CD274 and neoplasm: Taking PD-L1 expression and bTMB into account, treatment options can be divided into the following three categories: Patients with negative PD-L1 expression or low tumor mutation (bTMB <20 mut/Mb) can be considered to be preferred to ICIs combination therapy due to the susceptibility to ICI monotherapy resistance; patients with strong positive PD-L1 expression or high tumor mutation (bTMB ≥20 mut/Mb) can be considered as preferred to ICIs combination therapy in view of their susceptibility to ICI treatment and their susceptibility to ICI monotherapy.